ARA-290 10mg
ARA-290 is an 11-amino acid peptide derived from helix B of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR) without erythropoietic effects. Research demonstrates neuroprotective and tissue-protective properties, with clinical trials in sarcoidosis-related neuropathy showing improvements in corneal nerve fiber density.
Sequence
Synthetic 11-amino acid peptide derived from EPO helix B
Market avg: $59.99 — save 42%
Volume pricing
Pay with USDC via Coinbase Commerce
Certificate of Analysis
Independently verified by Janoshik Analytical
Test ID
JAN-ARA290-2026-001
Purity
98.9%
Method
HPLC-MS
Batch
ARA-2026-01A
Test Date
February 1, 2026
Identity
Confirmed
Storage Requirements
Lyophilized
2-8°C, protect from light
Reconstituted
2-8°C, use within 21 days
EPO-derived tissue-protective peptide. Does not stimulate erythropoiesis.
Published Research
2 peer-reviewed studies
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Brines M, Dunne AN, van Velzen M, et al. — Molecular Medicine, 2015
Clinical trial demonstrating ARA-290 improvements in neuropathic symptoms and metabolic parameters.
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor
Brines M, Grasso G, Fiordaliso F, et al. — Proceedings of the National Academy of Sciences, 2004
Discovery of the tissue-protective receptor complex that ARA-290 targets.
Related Products
Research use only. All products are sold strictly for in-vitro research purposes only. Not for human consumption. Information provided references published research literature. No medical claims are made or implied.